January 25, 2017


Can Slow Selling Heart Drug Entresto Perk Up in 2017? Novarits Hopes So

By Sten Stovall

Sales of Novartis’ Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug’s sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.

read full article >